9 New Drugs for Primary Care: Q3 2018

Early Responsive Parenting Intervention Shows Modest, Short-Term Impact on Childhood Obesity

Slideshow

Which drugs are most important for your patients? Scroll through our quick slideshow to find out.

It's the end of the third quarter, which means Patient Care has scoured all of the newly FDA-approved drugs and found 9 we believe every primary care physician should know about. Find details in the slideshow below about the first generic version of the EpiPen, a first-in-class oral antibiotic acne treatment, and 7 other noteworthy drugs.

new FDA drugs approved for primary care, third quarter, medications

For a quick review of primary care drugs approved in the first quarter of 2018, please go to 9 New Drugs for Primary Care: Q1 2018

For a quick review of primary care drugs approved in the second quarter of 2018, please go to 10 New Drugs for Primary Care: Q2 2018

Related Content

Breakthroughs in Atopic Dermatitis with Linda Stein Gold, MD: Primary Viewpoints Podcast

New data shows that early-life responsive parenting can lower childhood BMI, but effects diminished by age 9, highlighting the need for ongoing obesity prevention efforts.

Linda Stein Gold, MD;Sydney Jennings

March 9th 2025

Epinephrine Nasal Spray Shows Rapid Symptom Relief in Children: Daily Dose

“I think it’s important to have a lot of tools in our toolbox, and [tapinarof cream 1%] is one that gives us great flexibility," said Linda Stein Gold, MD.

Primary Viewpoints: Immunizations with Dr Steven P. Furr

Your daily dose of the clinical news you may have missed.

Keith A. Reynolds

October 1st 2024

Cost of Semaglutide, Tirzepatide Prohibitive Despite Significant Benefits

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Steven P. Furr, former president of the American Academy of Family Physicians.

Atopic Dermatitis Update: Roflumilast 0.15% Cream Shows Long-Term Safety and Efficacy Plus Benefit with Proactive Use

A new economic evaluation estimates that semaglutide would need to drop its current price by 81.9% and tirzepatide by 30.5% to be cost effective.

Roflumilast 0.15% Cream Shows Long-Term Safety and Efficacy Plus Benefit with Proactive Use / image Eric Simpson, MD, MRC, Oregon Health & Science University

Early Responsive Parenting Intervention Shows Modest, Short-Term Impact on Childhood Obesity

Improvement in AD signs and symptoms continued through 56 weeks of treatment with the PDE4 inhibitor including when used just twice weekly as prophylaxis.

Related Content

Breakthroughs in Atopic Dermatitis with Linda Stein Gold, MD: Primary Viewpoints Podcast

New data shows that early-life responsive parenting can lower childhood BMI, but effects diminished by age 9, highlighting the need for ongoing obesity prevention efforts.

Linda Stein Gold, MD;Sydney Jennings

March 9th 2025

Epinephrine Nasal Spray Shows Rapid Symptom Relief in Children: Daily Dose

“I think it’s important to have a lot of tools in our toolbox, and [tapinarof cream 1%] is one that gives us great flexibility," said Linda Stein Gold, MD.

Primary Viewpoints: Immunizations with Dr Steven P. Furr

Your daily dose of the clinical news you may have missed.

Keith A. Reynolds

October 1st 2024

Cost of Semaglutide, Tirzepatide Prohibitive Despite Significant Benefits

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Steven P. Furr, former president of the American Academy of Family Physicians.

Atopic Dermatitis Update: Roflumilast 0.15% Cream Shows Long-Term Safety and Efficacy Plus Benefit with Proactive Use

A new economic evaluation estimates that semaglutide would need to drop its current price by 81.9% and tirzepatide by 30.5% to be cost effective.